SKYEPHARMA PLC
Form 6-K
May 08, 2006

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

FOR IMMEDIATE RELEASE

SkyePharma PLC

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flut

LONDON, ENGLAND, 8 May, 2006 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces today that Kos Pharmaceuticals, Inc. (Nasdaq: KOSP) ("Kos") to jointly develop Flutiform , SkyePharma's no chronic obstructive pulmonary disease ("COPD"). Kos will have exclusive rights to market Fluti of first negotiation in Canada. SkyePharma could receive up to $165 million in milestone pay and revenue targets (of which $25 million has been paid upfront) together with royalties star US represents the largest market opportunity for Flutiform . SkyePharma remains in negotiation and other markets around the world.

SkyePharma's Chief Executive, Frank Condella, said: "We are delighted to announce this partn product Flutiform . Kos has a tremendous track record of successful marketing with its cholester years, sales of Niaspan have increased at a compound annual growth rate of over 50%, helpi pharmaceutical company in the United States in 2005 (and the sixth fastest growing of all US respiratory market with its recently acquired inhaled steroid product, Azmacort®. Kos currently on the cardiovascular and respiratory markets which it plans to increase and we expect Kos to h the time that Flutiform is launched. We believe Kos brings a therapeutically focused marke commercial potential of Flutiform in the key US market."

Adrian Adams, President and Chief Executive Officer of Kos, said: "We are very pleased with Flutiform for the asthma indication and are excited about this commercial opportunity in a ver This strategic partnership should broaden our presence in the respiratory area, and provides Azmacort®, our inhaled corticosteroid therapy. Our partnership with SkyePharma is another excel model that includes measured and therapeutically aligned investments to fortify our R&D pipeli scientific in-licensing activities. In addition, it provides an opportunity to diversify another potentially significant revenue generating opportunity anticipated in 2009, further least two products a year through the end of the decade, beginning in 2007."

Flutiform consists of a unique fixed-dose combination of the long-acting bronchodilator fluticasone in a proprietary metered-dose aerosol inhaler with a dose counter. The produc proprietary formulation technology, designed to stabilise the active components and thereby prolonged storage, provides patent protection for Flutiform to 2019. Flutiform is curren indication of asthma in adults and adolescents and is expected to be submitted for approval by to reach the market in 2009. By then the US market for combination treatments for asthma and COPD

Conference call later today

Senior management from Kos and SkyePharma will host a conference call at 1330 BST / 0830 EDT available live via the Internet by accessing the website of either company at www.kospharm. presentation slides will also be available. Please go to the respective website at least register, download and install any necessary audio software. Those who cannot access the web calling +1-913-312-1295, confirmation code 6963745. A replay will also be available on both w and entering confirmation code 6963745 from 1130 EDT today until 2359 EDT on Friday, May 12, 2006

For further information please contact:

SkyePharma PLC

Frank Condella, Chief Executive Officer +1 201 843 9500 x 6
Peter Laing, Director of Corporate Communications
Sandra Haughton, US Investor Relations

Kos Pharmaceuticals, Inc.

Adrian Adams, President and Chief Executive Officer +1 201 843 9500 x 6
John J. Howarth, VP, Investor Relations and Corporate Affairs
Nichol Harber, Senior Manager, Investor Relations & Corporate Communications

Buchanan Communications

Tim Anderson / Mark Court / Rebecca Skye Dietrich

Notes for editors

About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te
and more effective drug formulations. There are now twelve approved products incorporating Skye
oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabi
www.skyepharma.com.

About Kos Pharmaceuticals
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in devel
manufacturing and marketing proprietary prescription products for the treatment of chronic diseas
million in 2005 and currently has a market capitalisation in excess of $2 billion. The Company's
strategy is to reformulate existing pharmaceutical products with large market potential to improv
compliance. The Company currently markets Niaspan® and Advicor® for the treatment of cholesterol
treatment of asthma, Cardizem® LA for the treatment of hypertension and angina, and Teveten® and
hypertension. Kos is developing additional products, has proprietary drug delivery technologies i
metered-dose inhalation administration and is pursuing certain strategic business development and
information, visit www.kospharm.com.

About the treatment of asthma
Asthma is an inflammatory condition that makes the airways in the lung (bronchi) abnormally r
dust, pollen or cold air, resulting in constriction of the bronchi and difficulty in breathi
treated with two types of therapy: an anti-inflammatory drug that addresses the under
bronchodilator that opens the airways, relieving the symptoms and allowing patients to breat
bronchodilators although useful for treating acute asthma attacks have now largely been
prevention by long-acting bronchodilators that provide symptom relief for 12 hours (particularl
can be taken orally but most are inhaled, with the active drug delivered to the inner surf
device, either a metered-dose aerosol inhaler (MDI) or a breath-actuated dry powder inhaler (D
is expected to exceed $20 billion by 2010, with use in COPD, another inflammatory lung con
billion. The US market accounts for approximately half of the global total.

The fastest-growing part of this market is combination treatments, which combine a long-acting
in a single delivery device. Combinations are not only more convenient for patients than carryin
been shown to optimise the efficacy of the individual agents. Sales of GlaxoSmithKline's com
already exceed $6 billion, of which half is in the US, and AstraZeneca's Symbicort (which is no
billion. By 2010 the combination category is expected to account for over half of the asthma/COPD

About Flutiform
SkyePharma's product Flutiform consists of a unique fixed-dose combination of the long-actin
inhaled steroid fluticasone in a proprietary non-CFC metered-dose aerosol inhaler with a dose
of bronchodilation and has a rapid onset of action (1-3 minutes). By contrast salme
GlaxoSmithKline's Advair/Seretide, also provides 12 hours of bronchodilation but needs up to
effect. The inhaled steroid fluticasone (a component of Advair/Seretide) has low systemic
better safety and efficacy profile than budesonide, the steroid used in AstraZeneca's Symbi
inhaled steroid in the US. The proprietary SkyeDry formulation technology employed in Flutifo
components and thereby ensure a reproducible dose even after prolonged storage, provides paten
be available in two dose combinations with each dose delivering 10 microgrammes of formoterol w
fluticasone.

Flutiform completed its Phase II trial in asthma in 2005. The results confirmed that Flut
component drugs had been taken separately, with rapid onset of bronchodilation that was mai
drug-drug interactions and no safety concerns.

Following discussions with the FDA on the Phase II trial results, the Phase III trial of Fluti
2006. The trial programme is on track for SkyePharma's target of regulatory submission in
believes that Flutiform should reach the US market in 2009.

Certain statements in this news release are forward-looking statements and are made in reliance U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio statements are reasonable, it can give no assurance that these expectations will materialize. B risks and uncertainties, actual results may vary significantly from those expressed or impli based upon a number of factors, which are described in SkyePharma's 20-F and other documents on cause differences between actual results and those implied by the forward-looking statements c without limitation, risks related to the development of new products, risks related to obtainin for existing, new or expanded indications of existing and new products, risks related to SkyePh on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability maintain or expand market share in the face of changes in customer requirements, competition an to regulatory compliance, the risk of product liability claims, risks related to the ownership risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga forward-looking statement to reflect events or circumstances after the date of this release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: May 08, 2006